Zhitong Finance App News, HiCisco (002653.SZ) issued an announcement. The company recently received the “Notice of Acceptance” of the marketing license application for the new indications of the innovative drug Cligabarin Benzenesulfonate capsules issued by the State Drug Administration. This time, the marketing license application for this product to treat neuropathic pain symptoms in adults has been accepted.

Cligabarin benzenesulfonate capsules are a new third-generation voltage-gated calcium channel modulator with independent intellectual property rights developed by the company. It can inhibit the internal flow of calcium ions and reduce the release of neurotransmitters such as glutamate, norepinephrine, and P substance with high affinity, thereby relieving central sensitization, and has anti-seizure, analgesic, and anxiolytic activity.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.